Alterity Therapeutics (ATHE) Cash from Discontinued Operations (2009 - 2016)
Alterity Therapeutics (ATHE) recorded quarterly Cash from Discontinued Operations of 465813.11 in Q4 2016, up 85.85% quarter-over-quarter from 3291344.0 in Q4 2010.
Alterity Therapeutics (ATHE) Cash from Discontinued Operations (2009 - 2016) Analysis & Trends
Alterity Therapeutics' Cash from Discontinued Operations history runs 3 years deep, the most recent figure standing at 465813.11 for Q4 2016.
- In Q4 2016, Cash from Discontinued Operations changed N/A year-over-year to 465813.11; the TTM figure through Dec 2016 stood at 5356747.11 (changed N/A YoY), while the FY2024 annual figure was 12605824.0, changed N/A from the prior year.
- Cash from Discontinued Operations was 465813.11 for Q4 2016 at Alterity Therapeutics, up from 3291344.0 in the prior quarter.
- In the past five years, Cash from Discontinued Operations ranged from a high of 465813.11 in Q4 2016 to a low of 465813.11 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -59.14 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -465,813.11 |
| Dec 31, 2016 | -465,813.11 |
| Dec 31, 2010 | -3.29 Mn |
| Dec 31, 2010 | -3.29 Mn |
| Dec 31, 2009 | -1.60 Mn |
| Dec 31, 2009 | -1.60 Mn |